Related references
Note: Only part of the references are listed.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas et al.
CLINICAL CANCER RESEARCH (2010)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Jill C. Rubinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
Jonas N. Sondergaard et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
DRUG DISCOVERY Inhibitors that activate
Karen Cichowski et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy
Keiran S. M. Smalley et al.
CANCER RESEARCH (2009)
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Jean Philippe Arnault et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increasing Burden of Melanoma in the United States
Eleni Linos et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
Keith T. Flaherty et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
Antitumor activity of PLX4032, a selective V600EB-Raf inhibitor, as monotherapy and in combination with capecitabine +/- bevacizumab in a colorectal cancer xenograft model
K. Kolinsky et al.
EJC SUPPLEMENTS (2008)
Short guidelines - Malignant melanoma of the skin
Claus Garbe et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors
Savithri Ramurthy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results
Friederike Egberts et al.
ONKOLOGIE (2008)
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Claudia Wellbrock et al.
PLOS ONE (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sreenath V. Sharma et al.
GENES & DEVELOPMENT (2007)
Management of metastatic melanoma
Hussein A. Tawbi et al.
SEMINARS IN ONCOLOGY (2007)
Selective Raf inhibition in cancer therapy
Vladimir Khazak et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine
D. Nashan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2007)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
MP Hoeflich et al.
CANCER RESEARCH (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
L Zhuang et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma
F Meier et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
KV Bhatt et al.
ONCOGENE (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites
Y Cohen et al.
CLINICAL CANCER RESEARCH (2004)
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria
XD Zhang et al.
ONCOGENE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
UK guidelines for the management of cutaneous melanoma
JAN Bishop et al.
BRITISH JOURNAL OF PLASTIC SURGERY (2002)
Share Paper
